What does the Eris Lifesciences Limited (ERIS) stock page cover?

Eris Lifesciences Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for ERIS?

Eris Lifesciences Limited is currently shown with a delayed price near ₹1,156.4, P/E 22.5.

Does the ERIS page provide investment advice?

No. The ERIS page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Stocks›Healthcare

Watch Alert

Eris Lifesciences Limited

ERIS · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,156.40

−₹7.20 (−0.62%)(1D)

₹1,069.0052 Week Range₹1,740.00

Anvest Score

61/100

Valuation

62/100

Quality

61/100

Growth

92/100

Health

53/100

Momentum

28/100

Valuation
62
Quality
61
Growth
92
Health
53
Momentum
28

Loading company profile…

More Page Context

Research at a glance

Eris Lifesciences Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,156.4

Market cap

₹16,024 Cr

P/E ratio

22.5

P/B ratio

4.11

Dividend yield

Not available

ROE

Not available

RSI 14

44.25

1Y return

Not available

Eris Lifesciences Limited FAQs

3 topics

Expand

Stocks›Healthcare

Watch Alert

Eris Lifesciences Limited

ERIS · NSE · Healthcare · As of 30 Oct 2026Delayed / Sandbox EOD Data

₹1,156.40

−₹7.20 (−0.62%)(1D)

₹1,069.0052 Week Range₹1,740.00

Anvest Score

61/100

Valuation

62/100

Quality

61/100

Growth

92/100

Health

53/100

Momentum

28/100

Valuation
62
Quality
61
Growth
92
Health
53
Momentum
28

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Eris Lifesciences Limited is an Indian pharmaceutical company focused on manufacturing and marketing branded generic and specialty drugs. It primarily operates within India, specializing in chronic and lifestyle-related therapeutic areas. The company holds a notable position in the Indian pharmaceutical market, particularly in segments like cardiology and diabetes.

Drug Manufacturers - Specialty & GenericFounded:2007CEO/MD:Amit BakshiHQ:Ahmedabad, Gujarat

Business profile as of 2026-08-25

Business at a Glance

The company operates in a single segment: pharmaceuticals, focusing on diabetes care, cardiac care, nutrition, CNS disorders, dermatology, neuropsychiatry, and gynecology.
Its product portfolio includes various dosage forms and key brands like Glimisave and Cyblex.

Revenue growth: +8.1%FY26 growth+22.9%3Y CAGR
EPS growth: +75.4%FY26 growth+17.3%3Y CAGR
CFO / PAT: 0.83×FY26

What Looks Strong

GrowthRevenue and net profit grew at +23% and +18% 3Y CAGR.

What to Watch

TrendPrice is 14% below its 200-day moving average, indicating a weak long-term price trend.

Reports a single operating segment in its results filings.
Eris Lifesciences develops, manufactures, and markets branded pharmaceutical products, primarily in the chronic and lifestyle disease segments.
The company generates revenue by selling these specialty and generic drugs to healthcare professionals and patients through its extensive sales and distribution network across India.

FY26 (consolidated): revenue ₹3,129 cr, up 8% from ₹2,894 cr in FY25; net profit ₹648 cr, up 73% from ₹375 cr in FY25.
FY26 (consolidated): operating cash flow ₹538 cr (0.8× net profit); debt/equity 0.59×.
Latest quarter to Sep 2026 (consolidated): revenue ₹892 cr (up 13% year on year); net profit ₹187 cr.

The company has not reported material customer concentration
Financial statements mention long-term debt to working capital ratios

Loading company profile…

More Page Context

Research at a glance

Eris Lifesciences Limited with delayed price, financials, ownership context, and peer links.

Latest price

₹1,156.4

Market cap

₹16,024 Cr

P/E ratio

22.5

P/B ratio

4.11

Dividend yield

Not available

ROE

Not available

RSI 14

44.25

1Y return

Not available

Eris Lifesciences Limited FAQs

3 topics

Expand

AI Company ProfileSign in to generate AI briefing

AI Snapshot

Eris Lifesciences Limited is an Indian pharmaceutical company focused on manufacturing and marketing branded generic and specialty drugs. It primarily operates within India, specializing in chronic and lifestyle-related therapeutic areas. The company holds a notable position in the Indian pharmaceutical market, particularly in segments like cardiology and diabetes.

Drug Manufacturers - Specialty & GenericFounded:2007CEO/MD:Amit BakshiHQ:Ahmedabad, Gujarat

Business profile as of 2026-08-25

Business at a Glance

The company operates in a single segment: pharmaceuticals, focusing on diabetes care, cardiac care, nutrition, CNS disorders, dermatology, neuropsychiatry, and gynecology.
Its product portfolio includes various dosage forms and key brands like Glimisave and Cyblex.

Revenue growth: +8.1%FY26 growth+22.9%3Y CAGR
EPS growth: +75.4%FY26 growth+17.3%3Y CAGR
CFO / PAT: 0.83×FY26

What Looks Strong

GrowthRevenue and net profit grew at +23% and +18% 3Y CAGR.

What to Watch

TrendPrice is 14% below its 200-day moving average, indicating a weak long-term price trend.

Reports a single operating segment in its results filings.
Eris Lifesciences develops, manufactures, and markets branded pharmaceutical products, primarily in the chronic and lifestyle disease segments.
The company generates revenue by selling these specialty and generic drugs to healthcare professionals and patients through its extensive sales and distribution network across India.

FY26 (consolidated): revenue ₹3,129 cr, up 8% from ₹2,894 cr in FY25; net profit ₹648 cr, up 73% from ₹375 cr in FY25.
FY26 (consolidated): operating cash flow ₹538 cr (0.8× net profit); debt/equity 0.59×.
Latest quarter to Sep 2026 (consolidated): revenue ₹892 cr (up 13% year on year); net profit ₹187 cr.

The company has not reported material customer concentration
Financial statements mention long-term debt to working capital ratios

Eris Lifesciences Limited

Research at a glance

Eris Lifesciences Limited FAQs

Eris Lifesciences Limited

Business at a Glance

What Looks Strong

What to Watch

Research at a glance

Eris Lifesciences Limited FAQs

Related paths

Related insights

ASTRAZEN

APLLTD

COHANCE

Automated Forensic Screening: Detecting Cash Flow & Promoter Pledge Red Flags

Business at a Glance

What Looks Strong

What to Watch